media – Page 435 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

maker of Wegovy ‘skinny jab’ is funding NHS weight-loss services

The pharmaceutical company that makes Wegovy slimming jabs is funding the expansion of weight-loss services across England as it seeks to boost sales of its obesity drugs, the Observer can reveal. Novo Nordisk is paying the salaries of staff on NHS obesity teams and financing the launch and redesign of services, including giving £206,000 to a health partnership to transform its treatment of obesity. The Danish firm also has financial links to the co-chair of an NHS England weight management advisory group, and paid her almost £50,000 in lecture, consulting and other fees in just two years. Novo Nordisk’s funding arrangements are under the spotlight after an Observer investigation in March found it had paid £21.7m to UK health organisations and professionals in three years before the approval of its Wegovy injections for NHS use. In some cases, recipients of the funding went on to praise Wegovy or support its approval for use on the NHS without ...
- Source: drugdu
- 174
- April 4, 2023
A Testosterone Patch Is Being Developed For Menopausal Women—And It Could Be A World First

British researchers are developing a testosterone hormone patch to help combat symptoms linked to menopause, which if successful would be a world first that could help women secure better access to a hormone that is widely available to men but is subject to fierce debate over whether it should be used to alleviate symptoms of menopause in women. Testosterone patches are going to be tested to treat menopause symptoms. KEY FACTS The patch is being developed to help boost the sex drive of women with symptoms of menopause, according to news reports. Women’s natural production of testosterone drops drastically after menopause and low levels can cause issues including headaches, loss of libido, impaired focus and tiredness. While there are a plethora of testosterone replacement therapies available to men around the world, the few available to women are in the form of creams and gels, which are tough to dose properly and can ...
- Source: drugdu
- 210
- April 4, 2023
Direct Acting Antiviral Drugs For The Treatment Of Hepatitis C

This is fourth installment in my series on progress toward the elimination of Hepatitis C infection and disease. Read more about Hepatitis C in part one, part two and part three. Figure 1. The direct-acting antiviral targets in the hepatitis C virus replication cycle. NS3/4A … [+] In the previous articles of this series, I’ve outlined the seriousness and uncontrolled nature of hepatitis C. In the absence of a vaccine, the control and treatment of hepatitis C, much like that of HIV/AIDS, depends on the use of antiviral medications. Recent progress in the development of several highly active, anti-hepatitis C drugs has been a triumph of modern medicine. These drugs usher in an era of effective treatment and even elimination of hepatitis C both nationally and globally. Later in this series I will describe how these drugs have been used to eliminate hepatitis C from some countries and discuss how that success may be ...
- Source: drugdu
- 286
- April 4, 2023
In $2.6B cell and gene therapy expansion, Sartorius buys viral vector specialist Polyplus

[Before the Sartorius buyout, Polyplus had itself been expanding through multiple acquisitions. (Sartorius)] As the biopharma industry struggles with a dire shortage of viral vectors to make cell and gene therapies, contract manufacturers are busy beefing up their capabilities. In the latest example of biopharma’s ongoing investment in cell and gene therapy production, Sartorius has agreed to acquire French company Polyplus for 2.4 billion euros ($2.6 billion), the German CDMO said Friday. The deal gives Sartorius additional know-how in nucleic acid delivery, including transfection reagents and plasmid DNA design, all of which are key elements in the production of viral vectors for building cell and gene therapies. Formed in 2001, Polyplus employs about 270 people in several locations in France, Belgium, the U.S. and China. Before the Sartorius buyout, Polyplus had itself been expanding through M&A deals. In 2021, Polyplus bought Asia-Pacific-focused reagent supplier Biowire. ...
- Source: drugdu
- 285
- April 4, 2023
Nightmares and Dementia

Bad dreams are common and rarely are a sign of significant health concerns. However, several new studies have found potentially troubling associations between frequent or persistent nightmares and future cognition. These findings, along with recent insights into a potential intervention, have resulted in the top trending clinical topic this week. Previous investigations have found a link between sleep problems in adulthood, including nightmares, and the onset of neurodegenerative diseases. A recent analysis determined a possible association between distressing dreams during childhood and cognitive health concerns (see Infographic). A prospective, longitudinal analysis used data that included all people born in Britain during a single week in 1958. At age 7 years (in 1965) and 11 years (in 1969), mothers were asked to report whether their child experienced “bad dreams or night terrors” in the past 3 months. Among 6991 children (51% girls), 78.2% never had bad dreams, 17.9% had transient bad ...
- Source: drugdu
- 139
- April 4, 2023
Cancer drug leaflets for patients in Europe omit important facts

Cancer drug information leaflets for patients in Europe frequently omit important facts, while some are “potentially misleading” when it comes to treatment benefits and related uncertainties, researchers have found. Cancer is the biggest killer in Europe after heart conditions, with more than 3.7m new cases and 1.9m deaths every year, according to the World Health Organization. Medicines are a vital weapon against the disease. But critical facts about them are often missing from official sources of information provided to patients, clinicians and the public, according to a study led by researchers from King’s College London, Harvard Medical School and the University of Sydney, among others. “Regulated information sources for anticancer drugs in Europe fail to address the information needs of patients,” the study’s authors wrote in The BMJ journal. “If patients lack access to such information, clinical decisions may not align with their preferences and needs.” To receive and participate in medical care, patients ...
- Source: drugdu
- 217
- April 3, 2023
Frozen Strawberries Recalled As Hepatitis A Outbreak Has Left 2 Hospitalized

This news isn’t “berry” good if you like strawberries. A hepatitis A outbreak has resulted in at least five people infected and two people hospitalized, according to the Centers for Disease Control and Prevention (CDC). This, in turn, has left those selling certain brands of frozen organic strawberries in a bit of a jam. The U.S. Food and Drug Administration (FDA) has indicated that the likely culprits behind this outbreak are soft, juicy, and red. We’re talking about strawberries—not all strawberries, but those specifically imported in 2022 by a supplier from particular farms located in Baja California, Mexico. That’s led to two companies that used these strawberries in their frozen products and one retailer to issue voluntary recalls. One of these companies is California Splendor, Inc., based in San Diego, California. They’ve recalled certain lots of their Kirkland Signature 4-lb. bag Frozen Organic Whole Strawberries that have been sold in Costco stores in Los Angeles ...
- Source: drugdu
- 141
- April 3, 2023
Action To Reform Drug Pricing Increasingly Likely

The pressure on pharmacy benefit managers (PBMs) is ramping up. Both Congress and the Federal Trade Commission (FTC) are probing alleged anti-competitive practices by PBMs, and they’re doing so in parallel. Given the intense bipartisan pressure on PBMs, it’s increasingly likely that action of some kind will be taken to reform the drug pricing system. Last month, in a bipartisan vote of 18-9, the Senate Committee on Commerce, Science and Transportation advanced a bill, the Pharmacy Benefit Manager Transparency Act, to increase PBM transparency and crack down on what legislators and many policymakers are calling “deceptive practices.” Specifically, the bill stipulates what it deems are “unlawful activities” for PBMs to engage in. These include spread pricing – charging payers more than PBMs pay the pharmacy for a medication and then keeping the “spread” or difference as profit – and clawing back reimbursement payments from pharmacies. Regarding claw backs, PBMs assess direct and ...
- Source: drugdu
- 352
- April 3, 2023
After drug rejection, Vanda scores courtroom win over FDA in records case

Vanda Pharmaceuticals has scored a legal win in its long-running dispute with the FDA surrounding the agency’s 2018 rejection of Hetlioz in jet lag disorder. After months of litigation and years of back-and-forth, a court ruled that the FDA must turn over records relating to its denial of the label expansion, Vanda said in a Wednesday release (PDF). After the drug rejection in 2018, the company disputed the decision and last July requested an FDA hearing. The FDA “privately” agreed to the hearing but never published a notice in the Federal Register, meaning the process couldn’t move forward, Vanda said in its September lawsuit. Aside from its lawsuit, the company has been seeking records through a Freedom of Information Act request. In the suit, Vanda argued that the agency failed to act on its application and on its hearing request within timelines stipulated by the law. When Vanda filed the ...
- Source: drugdu
- 174
- March 31, 2023
mRNA vaccine beats infection for key defense against COVID-19, Stanford Medicine scientists find

Stanford Medicine researchers have shown that prior SARS-CoV-2 infection reduces killer T cells’ response to vaccination. These cells are crucial for eliminating the virus from the body. March 28, 2023 – By Bruce Goldman T cells are more difficult to measure than antibodies, but they play a crucial role in fighting pathogens.Kateryna Kon/Shutterstock.com The Pfizer/BioNTech mRNA vaccine directed at COVID-19 is much better than natural infection at revving up key immune cells called killer T cells to fight future infection by SARS-CoV-2, the virus that causes COVID-19, Stanford Medicine investigators have found. The scientists also showed, in a study published online in Immunity, that getting infected by SARS-CoV-2 before getting vaccinated lowers the vaccine’s otherwise exceptional ability to spur proliferation and activation of killer T cells directed at SARS-CoV-2. Their finding suggests that those hoping to avoid the manifold health risks associated with COVID-19 would do well to get vaccinated before they contract ...
- Source: drugdu
- 164
- March 31, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.